Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Biotech Stocks page aggregates 6 articles covering catalysts, earnings moves, and company updates to help you spot opportunities and manage biotech investments more confidently.
72 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Biotech stocks offer exciting growth potential, but with high risk. This guide explains how buying this biotech stock...
TransMedics has surged 104% over the last year, catching investors’ eyes. This guide breaks down the business, the ca...
As the world ages, demand for life-saving medical devices grows. This article breaks down three pragmatic reasons why...
A major fund just disclosed a sizable stake in Tango Therapeutics (TNGX), totaling about $9.5 million. This move shin...
What the arcturus (arct) 2025 earnings report may reveal isn’t just about a single quarter. This guide breaks down th...
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Biotech stocks can swing on clinical data and regulatory news. This guide digs into whether crispr therapeutics stock...
A forward-looking look at Compugen's 2025 earnings. Learn how pipeline progress, partnerships, and cash runway could ...
Unpack the essentials of fulgent genetics (flgt) earnings in plain language. This guide translates the earnings trans...
As mdxhealth (MDXH) 2025 earnings unfold, investors watch cash burn, pipeline progress, and strategic partnerships. T...